Inhibitor Therapeutics (INTI) Liabilities and Shareholders Equity (2012 - 2026)

Inhibitor Therapeutics (INTI) has 15 years of Liabilities and Shareholders Equity data on file, last reported at $1.4 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 68.18% year-over-year to $1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.0 million (down 53.88% YoY) and the FY2025 annual result came in at $2.5 million, down 55.9% from the prior year.
• Liabilities and Shareholders Equity eased to $1.4 million in Q1 2026, from $2.5 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $12.0 million in Q4 2022 to a low of $38517.0 in Q2 2022.
• A 5-year average of $5.5 million and a median of $5.7 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity plunged 71.79% — and 2023, when it surged 26273.64%.
• Tracing INTI's Liabilities and Shareholders Equity over 5 years: stood at $12.0 million in 2022, then slipped by 25.27% to $8.9 million in 2023, then plunged by 36.37% to $5.7 million in 2024, then tumbled by 55.9% to $2.5 million in 2025, then slumped by 42.92% to $1.4 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.4 million (Q1 2026), $2.5 million (Q4 2025), and $3.1 million (Q3 2025), per Business Quant data.